Scrutiny of Prostate Cancer Antigen 3 Effectiveness as an Assist of Prostatic Specific Antigen in Screening and Early Diagnosis of Prostate Cancer: A Review

Authors Information
Article Notes and Dates
To Cite : Azizi Jalilian F, Soleimani M, Alemi M, Bashiri A, Haghighat G. et al. Scrutiny of Prostate Cancer Antigen 3 Effectiveness as an Assist of Prostatic Specific Antigen in Screening and Early Diagnosis of Prostate Cancer: A Review, Nephro-Urol Mon. 2017 ;9(6):e13104. doi: 10.5812/numonthly.13104.
Copyright: Copyright © 2017, Nephro-Urology Monthly. .
Abstract
1. Introduction
2. Prostate Cancer Antigen 3 Gene
3. Tanique of Sampling
4. Results of Studies
5. PCA3 Score Cut-Off
6. Advantages of PCA3
7. Guidelines
8. Conclusion
References
  • 1. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016; 25(1): 16-27[DOI][PubMed]
  • 2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5)-86[DOI][PubMed]
  • 3. Sadjadi A, Nooraie M, Ghorbani A, Alimohammadian M, Zahedi MJ, Darvish-Moghadam S, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med. 2007; 10(4): 481-5[PubMed]
  • 4. Roshandel G, Boreiri M, Sadjadi A, Malekzadeh R. A diversity of cancer incidence and mortality in West Asian populations. Ann Glob Health. 2014; 80(5): 346-57[DOI][PubMed]
  • 5. Rahal AK, Badgett RG, Hoffman RM. Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review. PLoS One. 2016; 11(4)[DOI][PubMed]
  • 6. Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. Urology. 2015; 85(1): 92-100[DOI][PubMed]
  • 7. Prostate Cancer Early Detection. . National cancer comprehensive network clinical practice guidelines in oncology. 2016;
  • 8. Mottet N, Bellmunt J, Briers E. Eau-estro-siog guidelines on prostate cancer. Europ Association Urol.
  • 9. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn. 2004; 4(4): 513-26[DOI][PubMed]
  • 10. Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J Urol. 2013; 189(2): 422-9[DOI][PubMed]
  • 11. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23): 5975-9[PubMed]
  • 12. Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, Deliveliotis C. The novel prostate cancer antigen 3 (PCA3) biomarker. Int Braz J Urol. 2010; 36(6): 665-8[PubMed]
  • 13. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002; 62(9): 2695-8[PubMed]
  • 14. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007; 13(17): 5103-8[DOI][PubMed]
  • 15. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 2008; 389(1-2): 1-6[DOI][PubMed]
  • 16. Moradi Sardareh H, Goodarzi MT, Yadegar-Azari R, Poorolajal J, Mousavi-Bahar SH, Saidijam M. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals. Urol J. 2014; 11(6): 1952-8[PubMed]
  • 17. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008; 54(5): 1081-8[DOI][PubMed]
  • 18. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012; 188(5): 1726-31[DOI][PubMed]
  • 19. Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol. 2013; 190(2): 389-98[DOI][PubMed]
  • 20. Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, et al. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2015; 24(4): 677-82[DOI][PubMed]
  • 21. Merola R, Tomao L, Antenucci A, Sperduti I, Sentinelli S, Masi S, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J Experimental Clinical Cancer Res. 2015; 34(1): 15[DOI]
  • 22. Augustin H, Mayrhofer K, Pummer K, Mannweiler S. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate. 2013; 73(2): 203-10[DOI][PubMed]
  • 23. Salaglerski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a polish cohort. Anticancer Res. 2013; 33: 553-8
  • 24. De Luca S, Passera R, Cappia S, Bollito E, Randone DF, Porpiglia F. Pathological patterns of prostate biopsy in men with fluctuations of prostate cancer gene 3 score: a preliminary report. Anticancer Res. 2015; 35(4): 2417-22[PubMed]
  • 25. De Luca S, Passera R, Cappia S, Bollito E, Randone DF, Milillo A, et al. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies. BJU Int. 2014;
  • 26. Robert G, Jannink S, Smit F, Aalders T, Hessels D, Cremers R, et al. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate. 2013; 73(2): 113-20[DOI][PubMed]
  • 27. Batura D, Gopal Rao G. The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother. 2013; 68(2): 247-9[DOI][PubMed]
  • 28. Pepe P, Aragona F. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res. 2011; 31(12): 4445-9[PubMed]
  • 29. Xue WJ, Ying XL, Jiang JH, Xu YH. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: a meta-analysis. J Cancer Res Ther. 2014; 10 Suppl-21[DOI][PubMed]
  • 30. Mottet N, Bellmunt J, Briers E. Eau-estro-siog guidelines on prostate cancer. . Europ Association Urol. 2016;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Nephro-Urology Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check